Heterologous ad26.COV2.S prime and mRNA-based boost COVID-19 vaccination regimens: the SWITCH trial protocol

Author(s):
Sablerolles, R.S.G.; Goorhuis, A.; GeurtsvanKessel, C.H.; Vries, R.D. de; Huckriede, A.L.W.; Koopmans, M.P.G.; Lafeber, M.; Postma, D.F.; Baarle, D. van; Visser, L.G. (0000-0002-3600-9782); Dalm, V.A.S.H.; Kootstra, N.A.; Rietdijk, W.J.R.; Kuy, P.H.M. van der
Published
2021
Publication type
Article / Letter to editor
SARS-CoV-2COVID-19Homologous vaccination regimenHeterologous vaccine regimenrandomized clinical trialAd26.Cov2.SBNT162.b2mRNA1273 & nbsp
Date issued
2021-09-24
Language
English
Publisher
FRONTIERS MEDIA SA
Is part of
Frontiers in Immunology
hdl
1887/3247611
doi
10.3389/fimmu.2021.753319
URL
https://www.frontiersin.org/articles/10.3389/fimmu.2021.753319/pdf